

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of.:

ATLAS Daphne et al

Serial No.:

10/522,766

Filed:

February 27, 2006

For:

TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI-OXIDANT

COMPOUNDS

Attorney Docket:

Group Art Unit:

29287

1614

Examiner:

Meghan R. Finn

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ELECTION

Sir:

This is in response to the United States Patent and Trademark Restriction Office Action mailed December 27, 2007, which response is being made on or before January 27, 2008, and for which no extension of time fee is due.

Applicants hereby elect Group II, namely Claims 1 - 12, drawn to a method of treating multiple sclerosis with the compounds of group I.

With respect to the species requirements, Applicants select:

Compound J (N-acetyl cystein amide)

It is believed that claims 1 -12 are readable on the elected species.

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Group.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Date: January 15, 2008